[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 53 of about 53
1. Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS: A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer; 2008 Oct 1;113(7):1632-40
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
  • RESULTS: Thirty-eight patients with treatment-naive American Joint Committee on Cancer stage IV melanoma (8 patients with M1a disease, 6 patients with M1b disease, and 24 patients with M1c disease) were enrolled.
  • Responses were observed in patients with M1a disease and in patients with M1c disease.
  • Sixteen patients had stable disease (15 patients progressed).
  • CONCLUSIONS: The current results indicated that it is safe to administer HD IL-2 sequentially with temozolomide and that this combination has lower toxicity than previously used concurrent biochemotherapy regimens.
  • However, The ORR and the durability of responses with this combination did not exceed those of single-agent HD IL-2.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / analogs & derivatives. Interleukin-2 / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer. 2013 Feb 15;119(4):924
  • (PMID = 18720480.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA121973
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


2. Aslam S, Santha T, Leone A, Wilcox C: Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int; 2006 Dec;70(12):2109-15
Hazardous Substances Data Bank. AMLODIPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.
  • Patients with end-stage renal disease (ESRD) receiving hemodialysis (HD) treatment have a markedly shortened life expectancy in large part owing to cardiovascular disease (CVD), not explained by established risk factors.
  • We tested the hypothesis that therapy with valsartan, an angiotensin receptor blocker and amlodipine, an antioxidant calcium channel blocker will reduce oxidative stress and the plasma levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase.
  • We undertook a double blind, crossover study of equi-antihypertensive treatment with amlodipine and valsartan for 6 weeks each to test our hypothesis.
  • Both treatments significantly reduced GSSG:GSH, 8-hydroxy 2-deoxyguanosine, ADMA, and SDMA levels and amlodipine reduced 13-HODE.
  • We conclude that hypertensive patients with ESRD receiving HD have evidence of extensive oxidation of lipids, thiols, proteins, and nucleic acids and methylation of arginine that could contribute to CVD.
  • Many of these changes can be reduced by short-term treatment with amlodipine and valsartan.
  • [MeSH-major] Amlodipine / administration & dosage. Angiotensin II Type 1 Receptor Blockers / administration & dosage. Arginine / analogs & derivatives. Calcium Channel Blockers / administration & dosage. Kidney Failure, Chronic / drug therapy. Tetrazoles / administration & dosage. Valine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Pressure / drug effects. Cross-Over Studies. Female. Humans. Hypertension, Renal / drug therapy. Hypertension, Renal / metabolism. Male. Methylation / drug effects. Middle Aged. Oxidative Stress / drug effects. Renal Dialysis. Valsartan

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VALSARTAN .
  • Hazardous Substances Data Bank. L-Valine .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Kidney Int. 2006 Dec;70(12):2053-5 [17136131.001]
  • (PMID = 17063175.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR020359
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Calcium Channel Blockers; 0 / Tetrazoles; 1J444QC288 / Amlodipine; 30315-93-6 / N,N-dimethylarginine; 80M03YXJ7I / Valsartan; 94ZLA3W45F / Arginine; HG18B9YRS7 / Valine
  •  go-up   go-down


3. Schleinitz MD, DePalo D, Blume J, Stein M: Can differences in breast cancer utilities explain disparities in breast cancer care? J Gen Intern Med; 2006 Dec;21(12):1253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Black, older, and less affluent women are less likely to receive adjuvant breast cancer therapy than their counterparts.
  • OBJECTIVE: To ascertain utilities from women of diverse backgrounds for the different stages of, and treatments for, breast cancer and to determine whether a treatment decision modeled from utilities is associated with socio-demographic characteristics.
  • PARTICIPANTS: A stratified sample (by age and race) of 156 English-speaking women over 25 years old not currently undergoing breast cancer treatment.
  • DESIGN AND MEASUREMENTS: We assessed utilities using standard gamble for 5 breast cancer stages, and time-tradeoff for 3 therapeutic modalities.
  • We incorporated each subject's utilities into a Markov model to determine whether her quality-adjusted life expectancy would be maximized with chemotherapy for a hypothetical, current diagnosis of stage II breast cancer.
  • RESULTS: Median utilities for the 8 health states were: stage I disease, 0.91 (interquartile range 0.50 to 1.00); stage II, 0.75 (0.26 to 0.99); stage III, 0.51 (0.25 to 0.94); stage IV (estrogen receptor positive), 0.36 (0 to 0.75); stage IV (estrogen receptor negative), 0.40 (0 to 0.79); chemotherapy 0.50 (0 to 0.92); hormonal therapy 0.58 (0 to 1); and radiation therapy 0.83 (0.10 to 1).
  • Utilities for early stage disease and treatment modalities, but not metastatic disease, varied with socio-demographic characteristics.
  • One hundred and twenty-two of 156 subjects had utilities that maximized quality-adjusted life expectancy given stage II breast cancer with chemotherapy.
  • Age over 50, black race, and low household income were associated with at least 5-fold lower odds of maximizing quality-adjusted life expectancy with chemotherapy, whereas women who were married or had a significant other were 4-fold more likely to maximize quality-adjusted life expectancy with chemotherapy.
  • CONCLUSIONS: Differences in utility for breast cancer health states may partially explain the lower rate of adjuvant therapy for black, older, and less affluent women.
  • Further work must clarify whether these differences result from health preference alone or reflect women's perceptions of sources of disparity, such as access to care, poor communication with providers, limitations in health knowledge or in obtaining social and workplace support during therapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] WMJ. 1999 Dec;98(8):37-9 [10639893.001]
  • [Cites] J Gen Intern Med. 2005 Jan;20(1):38-44 [15693926.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3302-17 [10986064.001]
  • [Cites] Oncol Nurs Forum. 2000 Nov-Dec;27(10):1555-64 [11103374.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1455-61 [11230491.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1577-85 [11401308.001]
  • [Cites] Natl Vital Stat Rep. 2001 Sep 21;49(8):1-113 [11591077.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):471-3 [11929941.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2844-54 [12115371.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1759-66 [12365025.001]
  • [Cites] South Med J. 2002 Oct;95(10):1145-8 [12425498.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):134-47 [12491515.001]
  • [Cites] Cancer Metastasis Rev. 2003 Mar;22(1):55-65 [12716037.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(1):21-31 [14531494.001]
  • [Cites] BMC Med Inform Decis Mak. 2001;1:2 [11545684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):34-42 [14697418.001]
  • [Cites] J Gen Intern Med. 2004 Feb;19(2):184-94 [15009798.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Med Decis Making. 2005 May-Jun;25(3):301-7 [15951457.001]
  • [Cites] Arch Fam Med. 1999 Nov-Dec;8(6):521-8 [10575392.001]
  • [Cites] Med Decis Making. 2000 Jan-Mar;20(1):72-8 [10638539.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):311-7 [12491494.001]
  • [Cites] Arch Intern Med. 2003 Jan 13;163(1):49-56 [12523916.001]
  • [Cites] Ann Intern Med. 2003 Jan 21;138(2):90-7 [12529090.001]
  • [Cites] J Eval Clin Pract. 2003 Feb;9(1):69-82 [12558704.001]
  • [Cites] Med Decis Making. 2003 Mar-Apr;23(2):167-76 [12693879.001]
  • [Cites] Prev Med. 2004 Jul;39(1):1-10 [15207980.001]
  • [Cites] CA Cancer J Clin. 2003 Nov-Dec;53(6):342-55 [15224974.001]
  • [Cites] Clin Prostate Cancer. 2004 Jun;3(1):31-7 [15279688.001]
  • [Cites] Health Serv Res. 1972 Summer;7(2):118-33 [5044699.001]
  • [Cites] Med Decis Making. 1982 Winter;2(4):449-62 [7182703.001]
  • [Cites] J Health Econ. 1986 Mar;5(1):1-30 [10311607.001]
  • [Cites] Med Care. 1989 Mar;27(3 Suppl):S190-204 [2522159.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86 [2593165.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):326-31 [8321261.001]
  • [Cites] Med Decis Making. 1993 Jul-Sep;13(3):212-7 [8412549.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1395-402 [8839544.001]
  • [Cites] Breast Cancer Res Treat. 1996;39(3):261-73 [8877006.001]
  • [Cites] Breast Cancer Res Treat. 1996;40(1):65-74 [8888153.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):327-37 [8909641.001]
  • [Cites] Med Decis Making. 1997 Jan-Mar;17(1):21-32 [8994148.001]
  • [Cites] Med Decis Making. 1997 Apr-Jun;17(2):136-41 [9107608.001]
  • [Cites] Oncol Nurs Forum. 1998 Apr;25(3):555-62 [9568610.001]
  • [Cites] Oncol Nurs Forum. 1998 Jun;25(5):887-95 [9644705.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1409-15 [10451447.001]
  • [Cites] J Clin Epidemiol. 1999 Nov;52(11):1047-53 [10526998.001]
  • [Cites] Med Care. 2005 Feb;43(2):141-8 [15655427.001]
  • [Cites] Med Care. 2000 Sep;38(9 Suppl):II160-4 [10982102.001]
  • (PMID = 16961753.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NICHD NIH HHS / HD / HD43447
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC1924747
  •  go-up   go-down


Advertisement
4. Shahidi M, Kamangari N, Ashley S, Cunningham D, Horwich A: Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol; 2006 Jan;78(1):1-5
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease.
  • BACKGROUND: Short course chemotherapy followed by radiotherapy is a standard treatment for early Hodgkin's disease.
  • There is yet no consensus regarding the appropriate radiotherapy portal following chemotherapy.
  • A good guide to the adjuvant radiotherapy field is the site of relapse in patients treated with chemotherapy alone.
  • PATIENTS AND METHODS: From 1980 to 1996, 61 patients with stage I and II supradiaphragmatic Hodgkin's disease were treated with chemotherapy alone at the Royal Marsden Hospital.
  • Twenty patients (83%) relapsed in the initially involved sites of disease and this was the sole site of recurrence in 11 (45%) of patients.
  • Review of detailed imaging data (available in 9 out of 11 patients with recurrences in initial sites of disease) showed that the relapses were always in the initially involved nodes.
  • CONCLUSION: After chemotherapy alone in early stage HD most initial recurrences are nodal.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309770.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


5. Huang HQ, Jiang WQ, Wang W, Xu GC, Zhang L, He YJ, Sun XF, Zhou ZM, Liu DG, Xu RH, Lin TY, Teng XY, Liu MZ, Su YS, Li YH, Lin XB, Guan ZZ: [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality]. Ai Zheng; 2002 Dec;21(12):1345-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical results of 295 patients with Hodgkin's disease treated by chemotherapy-predominant comprehensive modality].
  • BACKGROUND & OBJECTIVE: Hodgkin's disease (HD) is a chemo- and radio-sensitive hematologic malignancy.
  • At present, improvement of cure rate, reduction of long-term toxicity, and maintenance of good quality of life are the major issues in the treatment of HD.
  • METHODS: The results of 295 patients with histology-proven HD from 1970 to 2000, especially from 1980 to 2000 were analyzed.
  • RESULTS: A total of 295 HD patients were treated by chemotherapy-predominant comprehensive modality.
  • The 5, 10, and 20 years overall survival for 295 HD patients were 63.5%, 55.8%, and 47.1%, respectively, with median survival time of 172.3 months (28-351.9 months) at the median follow-up time of 42.9 months (17-351.9 months).
  • The 5, 10, and 20 years overall survival and disease-free survival were 79.6%, 74.5%, and 66.8% as well as 74.5%, 69.4%, and 69.4% respectively for the patients treated with regular chemotherapy and radiotherapy from 1980 to 2000.
  • Multivariate analysis demonstrated that age over 45-year-old, B symptoms and stage III/IV were the main prognostic factors (P = 0.000, P = 0.035, and P = 0.047) in this clinical study.
  • The prognosis of the patients with stage I/II and nodular sclerosis was better in comparison to stages III/IV and other histologic subtypes.
  • CONCLUSIONS: Chemotherapy-predominant combined with involved fields irradiation play an important role in HD treatment with promising long term survival and lower late toxicities.
  • [MeSH-major] Hodgkin Disease / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Clinical Trials as Topic. Combined Modality Therapy. Drug Therapy. Female. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12520745.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Blakely ML, Shamberger RC, Norkool P, Beckwith JB, Green DM, Ritchey ML, National Wilms' Tumor Study Group: Outcome of children with cystic partially differentiated nephroblastoma treated with or without chemotherapy. J Pediatr Surg; 2003 Jun;38(6):897-900
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of children with cystic partially differentiated nephroblastoma treated with or without chemotherapy.
  • The purpose of this report is to examine the outcome of children with CPDN, after nephrectomy, treated with vincristine and dactinomycin based chemotherapy (+/- doxorubicin) or no chemotherapy.
  • Thirteen patients received chemotherapy, and 8 patients did not.
  • In the chemotherapy group the stage distribution was as follows: stage I (n = 10), stage II (n = 2), stage V (n = 1).
  • In the no-chemotherapy group, all 8 patients were stage I.
  • There were no cases of disease progression or recurrence in any patient.
  • In patients receiving chemotherapy, 30% (n = 4) had toxicities causing dose reduction.
  • For stage I patients, treatment with complete tumor resection appears to be as efficacious as nephrectomy plus chemotherapy.
  • Stage II patients also have excellent outcome when treated with tumor resection and postoperative vincristine and dactinomycin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Diseases, Cystic / drug therapy. Kidney Neoplasms / drug therapy. Wilms Tumor / drug therapy. Wilms Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Differentiation / drug effects. Child. Child, Preschool. Dactinomycin / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Nephrectomy. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12778388.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-42326; United States / NICHD NIH HHS / HD / K23-HD/RR01473-01
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin
  •  go-up   go-down


7. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ: Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol; 2002 Dec 18;40(12):2117-21
Hazardous Substances Data Bank. SIMVASTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early statin therapy restores endothelial function in children with familial hypercholesterolemia.
  • BACKGROUND: Endothelial function measured by flow-mediated dilation of the brachial artery (FMD) is used as a surrogate marker of cardiovascular disease (CVD).
  • Adult studies have shown that statins reverse endothelial dysfunction and therefore reduce the risk for future CVD.
  • The FMD was performed at baseline and at 28 weeks of treatment.
  • Upon treatment, the simvastatin FH group showed significant absolute reductions of total cholesterol (TC) (-2.16 +/- 1.04 mmol/l, 30.1%) and low-density lipoprotein cholesterol (LDL-C) (-2.13 +/- 0.99 mmol/l, 39.8%).
  • The absolute change of FMD after 28 weeks of therapy was inversely correlated to changes of TC (r = -0.31, p < 0.05) and LDL-C (r = -0.31, p < 0.05).
  • CONCLUSIONS: Our data show significant improvement of endothelial dysfunction towards normal levels after short-term simvastatin therapy in children with FH.
  • These results emphasize the relevance of statin therapy in patients with FH at an early stage, when the atherosclerotic process is still reversible.
  • [MeSH-major] Endothelium, Vascular / drug effects. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use. Hyperlipoproteinemia Type II / drug therapy. Simvastatin / therapeutic use
  • [MeSH-minor] Adolescent. Arteriosclerosis / prevention & control. Child. Female. Humans. Lipids / blood. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Familial Hypercholesterolemia.
  • Genetic Alliance. consumer health - Hypercholesterolemia.
  • MedlinePlus Health Information. consumer health - Statins.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Coll Cardiol. 2002 Dec 18;40(12):2122-4 [12505223.001]
  • (PMID = 12505222.001).
  • [ISSN] 0735-1097
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Lipids; AGG2FN16EV / Simvastatin
  •  go-up   go-down


8. Hollisaz MT, Khedmat H, Yari F: A randomized clinical trial comparing hydrocolloid, phenytoin and simple dressings for the treatment of pressure ulcers [ISRCTN33429693]. BMC Dermatol; 2004;4(1):18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized clinical trial comparing hydrocolloid, phenytoin and simple dressings for the treatment of pressure ulcers [ISRCTN33429693].
  • Many preventive and therapeutic approaches have been tried and new trials are evolving.
  • One relatively recent method is application of a hydrocolloid dressing (HD).
  • In this study we compared the therapeutic effects of HD on pressure ulcer healing with two other topical applications, phenytoin cream (PC) and simple dressing (SD).
  • METHODS: Ninety-one stage I and stage II pressure ulcers of 83 paraplegic male victims of the Iran-Iraq war were randomly allocated to three treatment groups.
  • RESULTS: Complete healing of ulcers, regardless of location and stage, was better in the HD group than the PC [23/31(74.19%) vs 12/30(40%); difference: 34.19%, 95% CI = 10.85-57.52, (P < 0.01)] or the SD [23/31(74.19%) vs 8/30(26.66%); difference: 47.53%, 95% CI = 25.45-69.61, (P < 0.005)] groups.
  • Complete healing of stage I ulcers in the HD group [11/13(85%)] was better than in the SD [5/11(45%); difference: 40%, 95% CI = 4.7-75.22, (P < 0.05)] or PC [2/9 (22%); difference: 63%, 95% CI = 29.69-96.3, (P < 0.005)] groups.
  • Complete healing of stage II ulcer in the HD group [12/18 (67%)] was better than in the SD group [3/19(16%); difference: 51%, 95% CI = 23.73-78.26, (P < 0.005)], but not significantly different from the PC group [10/21 (48%); difference: 19%, 95% CI = -11.47-49.47, (P > 0.05)].
  • This "per patient" analysis showed that complete ulcer healing in the HD group was better than in the PC [20/28(71.4%) vs 11/28 (39.3%); difference: 32.1%, 95% CI = 7.4-56.7, (P < 0.01)] or SD [20/28(71.4%) vs 8/27 (29.6%); difference: 41.8%, 95% CI = 17.7-65.8, (P < 0.005)] groups.
  • CONCLUSION: We deduced that HD is the most effective method investigated for treating stage I and II pressure ulcers in young paraplegic men.
  • [MeSH-major] Colloids / therapeutic use. Occlusive Dressings. Phenytoin / therapeutic use. Pressure Ulcer / drug therapy. Spinal Cord Injuries / complications
  • [MeSH-minor] Administration, Topical. Adult. Humans. Male. Severity of Illness Index. Wound Healing / drug effects

  • MedlinePlus Health Information. consumer health - Pressure Sores.
  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • Hazardous Substances Data Bank. PHENYTOIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Control Clin Trials. 2001 Apr;22(2):102-10 [11306148.001]
  • [Cites] Br J Nurs. 2000 Oct;9(19 Suppl):S6, S8, S10 passim [12271239.001]
  • [Cites] Arch Phys Med Rehabil. 1992 Feb;73(2):195-200 [1543418.001]
  • [Cites] Arch Phys Med Rehabil. 1992 May;73(5):463-9 [1580775.001]
  • [Cites] Clin Dermatol. 1991 Oct-Dec;9(4):585-91 [1822415.001]
  • [Cites] Paraplegia. 1994 Mar;32(3):150-8 [8008417.001]
  • [Cites] Phys Ther. 1994 Sep;74(9):812-23; discussion 824-5 [8066108.001]
  • [Cites] Ostomy Wound Manage. 1995 Mar;41(2):52-4, 56, 58 passim [7598778.001]
  • [Cites] Arch Phys Med Rehabil. 1996 Aug;77(8):744-9 [8702366.001]
  • [Cites] Yonsei Med J. 1996 Jun;37(3):181-5 [8826783.001]
  • [Cites] SCI Nurs. 1997 Dec;14(4):111-7 [9510832.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 1999 Mar;33(1):13-5 [10207960.001]
  • [Cites] Adv Wound Care. 1998 Oct;11(6):273-6 [10326343.001]
  • [Cites] Br J Community Nurs. 2002 Sep;7(9):451-60 [12362141.001]
  • [Cites] Arch Phys Med Rehabil. 1994 Aug;75(8):908-17 [8053799.001]
  • [Cites] Ostomy Wound Manage. 2003 Oct;49(10):52-7 [14652421.001]
  • [Cites] Chest. 2004 Jan;125(1):43-9 [14718419.001]
  • [Cites] Clin Orthop Relat Res. 1975 Oct;(112):89-100 [1192654.001]
  • [Cites] Paraplegia. 1981;19(4):235-47 [7290733.001]
  • [Cites] Arch Phys Med Rehabil. 1984 Oct;65(10):597-600 [6487064.001]
  • [Cites] Arch Surg. 1985 Mar;120(3):267-70 [3970664.001]
  • [Cites] Arch Dermatol. 1987 Jun;123(6):766-71 [3555355.001]
  • [Cites] Arch Dermatol. 1988 Jun;124(6):872-7 [3288123.001]
  • [Cites] J Rehabil Res Dev. 1989 Winter;26(1):63-74 [2645399.001]
  • [Cites] Int J Dermatol. 1989 Jun;28(5):347-50 [2666326.001]
  • [Cites] Scand J Plast Reconstr Surg Hand Surg. 1989;23(2):89-96 [2814388.001]
  • [Cites] Acta Derm Venereol Suppl (Stockh). 1989;149:1-10 [2694713.001]
  • [Cites] Int Angiol. 1989 Oct-Dec;8(4):224-8 [2634718.001]
  • [Cites] Am J Infect Control. 1990 Aug;18(4):257-68 [2206087.001]
  • [Cites] Paraplegia. 1990 May;28(4):269-71 [2235034.001]
  • [Cites] Rehabil Nurs. 1991 Jan-Feb;16(1):6-8 [1989050.001]
  • [Cites] Decubitus. 1991 Aug;4(3):47-8, 50, 52 passim [1872977.001]
  • [Cites] Br J Nurs. 2000 Jan 13-26;9(1):10-2, 14, 16 passim [10887841.001]
  • [Cites] Med J Malaysia. 1998 Dec;53(4):428-31 [10971989.001]
  • [Cites] Br J Nurs. 2000Jun 8-21;9(11):720-3 [11235265.001]
  • [Cites] Br J Nurs. 2002 Feb 28-Mar 13;11(4):284, 286-7 [11873220.001]
  • (PMID = 15601464.001).
  • [ISSN] 1471-5945
  • [Journal-full-title] BMC dermatology
  • [ISO-abbreviation] BMC Dermatol.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN33429693
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Colloids; 6158TKW0C5 / Phenytoin
  • [Other-IDs] NLM/ PMC545970
  •  go-up   go-down


9. Di Nicola M, Carlo-Stella C, Mariotti J, Devizzi L, Massimino M, Cabras A, Magni M, Matteucci P, Guidetti A, Gandola L, Gianni AM: High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Br J Haematol; 2004 Sep;126(6):815-20
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.
  • A very short, intensive paediatric chemotherapy programme was tested in a consecutive monoinstitutional group of 22 adult Burkitt's lymphoma (BL) patients.
  • After a 5-week induction phase of weekly infusions consisting of vincristine, cyclophosphamide, doxorubicin, high-dose (HD) methotrexate (MTX) plus leukovorin rescue, and intrathecal MTX or cytarabine (ARA-C), a consolidation phase including HD ARA-C plus cisplatin was given.
  • Responding patients achieving less than complete response (CR) after completion of the initial induction phase, were promptly shifted to a high-dose, stem cell supported sequential chemotherapy schema (R-HDS).
  • PATIENT CHARACTERISTICS: median age, 35.5 (range 18-76) years; Ann Arbor stage I-II/III-IV, 11/11; bulky disease, 15 patients; LDH > or = 460 U/l, 11 patients.
  • The median duration of the chemotherapy programme was 62 d (range, 43-94 d).
  • Seventeen patients achieved a CR (77%), one patient died of progressive disease and four partial responders following induction were converted to CR following R-HDS.
  • Of 17 patients in CR, one died of infectious toxicity while in CR, and one relapsed at 30 months and died of progressive disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15352985.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Provencio M, España P, Millán I, Sánchez A, Cantos B, Bonilla F: The management of stage I-II supradiaphragmatic Hodgkin's disease with chemotherapy alone. Leuk Lymphoma; 2003 Feb;44(2):263-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of stage I-II supradiaphragmatic Hodgkin's disease with chemotherapy alone.
  • The treatment of choice for patients with early stage Hodgkin's disease (HD) has been extended field or subtotal nodal irradiation.
  • Remission rates of over 95% have been obtained, however, about 5% of stage I and II patients will suffer from progressive disease while on therapy and an additional 15-20% will relapse.
  • Chemotherapy (Ch) alone has not been adequately tested in early-stage HD.
  • In this study, all HD stage I and II patients treated with Ch alone in the University Hospital "Clínica Puerta de Hierro" between 1980 and 1997 were reviewed.
  • Three (8.5%) patients died: two due to a second tumour (non-Hodgkin's lymphoma and myeloid acute leukaemia) and the other due to sepsis post-Ch.
  • In conclusion, we believe that death from HD in early-stage patients is unusual and mortality from causes other than HD occurs many years later.
  • Outside clinical trials due to the lack of clear prognostic factors, with the exception of specific situations, patients should be informed of all the possible alternatives as well as the consequences of the treatments employed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Disease Management. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Remission Induction. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12688343.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Zapatero A, López MA, Cerezo L, De Vidales CM, MarIn A, Pérez-Torrubia A: Stage I-III Hodgkin's disease: outcome and pattern of failure following treatment with radiation therapy and chemotherapy in a modern era. Hematology; 2002 Feb;7(1):43-50
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I-III Hodgkin's disease: outcome and pattern of failure following treatment with radiation therapy and chemotherapy in a modern era.
  • PURPOSE: To analyse the long term outcome, pattern of failure and treatment related complications after radiation therapy (RT) with or without chemotherapy for stage I-III Hodgkin's disease (HD).
  • MATERIAL AND METHODS: Detailed records from 86 patients with stage I-III HD treated between 1989 and 1998, were retrospectively reviewed.
  • Seventeen patients with favourable stage I-IIA were treated with RT alone, and the remaining 69 patients with combined modality treatment (CMT).
  • Patients treated with RT received extended-field or subtotal nodal irradiation (STNI) to a total dose of 36-54 Gy, and patients with CMT, received involved-field irradiation to a lower doses, 26-40 Gy.
  • The median follow-up time was 50 months (range 16-180).
  • RESULTS: The 10-year overall survival (OS) for the whole group was 96% (SE 2%), 100% for stage I, 95% for stage II and 100% for stage III patients.
  • Of potential prognostic factors analysed for statistical significance, only the response to chemotherapy (p=0.0393) was found to influence significantly OS rates.
  • Salvage treatment was effective in 10 of the 12 relapsed patients.
  • The 10-year freedom from treatment failure (FFTF) was 79% (SE 6%).
  • Although 8 (9.6%) of the 83 surviving patients developed late effects that could represent toxicity from the treatment, no patient died of late complications.
  • CONCLUSIONS: RT alone for favourable early stage HD attains good survival rates with a modest treatment related morbidity.
  • For patients with unfavourable stage II and stage III HD, CMT with limited RT provides a good to excellent prognosis.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12171776.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Pejsa V, Grgurević I, Kujundzić M, Martinović M, Stancić V, Donley K, Pavletic S: No adverse effect of ABVD chemotherapy in a patient with chronic hepatitis C and Hodgkin's disease. Wien Klin Wochenschr; 2004 Oct 30;116(19-20):695-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No adverse effect of ABVD chemotherapy in a patient with chronic hepatitis C and Hodgkin's disease.
  • There is insufficient information on the effects of chemotherapy protocols for Hodgkin's disease (HD) and the course of coexisting hepatitis C virus (HCV) infection.
  • A single literature case reported a patient with HD who developed fulminant hepatitis and hepatic coma after receiving chemotherapy.
  • The case described here is of a female patient previously exposed to prolonged war stress, complicated by intravenous drug abuse and chronic hepatitis C.
  • One year after diagnosis of HCV infection she was diagnosed with HD (nodular sclerosis type II, clinical stage IIIB).
  • The patient received six cycles of ABVD chemotherapy (doxorubicin, bleomycin, vinblastine and dacarbazine) resulting in complete remission of HD.
  • There was no hepatitis flare either during or after chemotherapy.
  • In conclusion, there were no adverse effects of the ABVD regimen on the course of HCV infection in this patient who was successfully treated for HD.
  • Because concurrent HCV infection and HD is extremely rare, we discuss here the possibility of the synergistic contribution of chronic war stress and hepatitis C infection in the pathogenesis of HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hepatitis C, Chronic / complications. Hodgkin Disease / complications. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Biopsy. Bleomycin / administration & dosage. Bleomycin / adverse effects. Combat Disorders / complications. Croatia. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Follow-Up Studies. Humans. Liver / pathology. Liver Function Tests. Neoplasm Staging. Remission Induction. Substance Abuse, Intravenous / complications. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941081.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


13. Montoto S, Camós M, López-Guillermo A, Bosch F, Cervantes F, Blandé J, Esteve J, Cobo F, Nomdedeu B, Campo E, Montserrat E: Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer; 2000 May 1;88(9):2142-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
  • BACKGROUND: Combination chemotherapy, including hybrid regimens, is the standard treatment for patients with advanced Hodgkin disease (HD).
  • Cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) is a hybrid chemotherapy in which cyclophosphamide is substituted for mechlorethamine, an agent that has been implicated as the cause of secondary malignancies.
  • METHODS: Seventy-three patients (37 males and 36 females; median age, 35 years) diagnosed with Stage III or IV HD or Stage II with bulky disease, B-symptoms, elevated erythrocyte sedimentation rate, or hilar adenopathy were treated with 8 courses of C-MOPP/ABV at a single institution during a 6-year period.
  • Radiotherapy (RT) was administered when bulky disease or residual masses were present.
  • Endpoints of the study were response to therapy, failure free survival (FFS), overall survival (OS), and toxicity.
  • After chemotherapy, 57 patients (78%) reached CR.
  • Two patients died during treatment because of sepsis and four due to disease progression.
  • CONCLUSIONS: C-MOPP/ABV induces CR with acceptable toxicity in a high proportion of advanced HD patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Bleomycin / administration & dosage. Bleomycin / adverse effects. Confidence Intervals. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Radiotherapy, Adjuvant. Remission Induction. Survival Rate. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10813727.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


14. Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M: Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol; 2000 Mar;30(3):146-52
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
  • BACKGROUND: The main form of cytotoxic treatment for advanced Hodgkin's disease (HD) is conventional dose multiagents chemotherapy.
  • As HD is not common in Japan, we conducted a phase II study of the commonly used combination chemotherapy (CCT) regimen established in the West for Japanese patients with advanced HD to confirm the efficacy and safety.
  • METHOD: Between October 1989 and February 1993, a multicenter phase II study of alternating CCT C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, vinblastine, bleomycin, dacarbazine) to evaluate its clinical usefulness for clinical stage (cS) II-IV HD was conducted by the Lymphoma Study Group of the Japan Clinical Oncology Group.
  • For 40 cS II and 27 cS III/IV patients the response rate was 95.0% with 90.0% CR and 88.9% with 74.1% CR, respectively.
  • Those of cS II and cS III/IV were 92.5 and 73.1%, respectively.
  • There was no significant difference between cS II and cS III/IV (p = 0.1025).
  • Those of cS II and cS III/IV were 77.5 and 65.7%, respectively.
  • There was no significant difference between cS II and cS III/IV (p = 0.2483).
  • There was GPT elevation in 4.5%, nausea/vomiting in 11.9% and CNS in 1.5% of patients, but there was no treatment-related death.
  • CONCLUSION: The C-MOPP/ABVd regimen for Japanese patients with advanced HD is considered to be one of the effective CCTs according to the results of the present phase II study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Prednisolone / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Survival Rate. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10798542.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; ABVD protocol; CMOPP protocol
  •  go-up   go-down


15. Klauber-Demore N, Kuzmiak C, Rager EL, Ogunrinde OB, Ollila DW, Calvo BF, Kim HJ, Meyer A, Dees C, Graham M 2nd, Collichio FA, Sartor CI, Metzger R, Carey LA: High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. Am J Surg; 2004 Oct;188(4):386-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
  • BACKGROUND: The purpose of this study was to evaluate the efficacy of high-resolution axillary ultrasound in detecting axillary lymph node metastases after neoadjuvant chemotherapy in patients with locally advanced breast cancer.
  • METHODS: Fifty-three patients with stage II or III breast cancer undergoing neoadjuvant chemotherapy who had a physical examination, high-resolution axillary ultrasound, and axillary lymph node dissection from January 1999 to September 2003 were included in this study.
  • CONCLUSIONS: A negative post-neoadjuvant chemotherapy high-resolution axillary ultrasound or physical examination does not predict pathologic node status, and this test has limited value in this setting.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Axilla. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15474431.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / 5K12 HD001441; United States / NCI NIH HHS / CA / CA58223; United States / NCRR NIH HHS / RR / M01 RR00046
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


16. Brenot-Rossi I, Bouabdallah R, Di Stefano D, Bardou VJ, Stoppa AM, Camerlo J, Sauvan R, Gastaut JA, Pasquier J: Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy. Eur J Nucl Med; 2001 Oct;28(10):1482-8
Hazardous Substances Data Bank. GALLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease: prognostic role of gallium scintigraphy after chemotherapy.
  • Evaluation of the response to therapy is important for optimal selection of treatment strategy in patients with Hodgkin's disease (HD).
  • Refractory disease requires intensive high-dose chemotherapy, whereas unnecessary treatment should be avoided in patients in complete remission.
  • The purpose of this study was to evaluate the contribution of gallium-67 scintigraphy in predicting the clinical outcome in patients with HD and mediastinal involvement on the basis of scan results at the end of chemotherapy.
  • Seventy-four patients with HD and mediastinal involvement were retrospectively investigated with 67Ga scintigraphy 72 h after injection of 220 MBq 67Ga citrate (planar and single-photon emission tomographic studies) following the completion of chemotherapy.
  • At the same time, they all underwent computed tomography (CT).
  • The disease status was newly diagnosed disease in 64 of the patients and relapse in 10.
  • Forty-one patients had stage I or II disease and 33 patients had stage III or IV disease.
  • Twenty-two patients had bulky disease on initial diagnosis.
  • At the end of chemotherapy, all 74 patients showed regression of the mass by more than 50% (50%-100%) on CT.
  • Patients were divided into two groups according to the positivity or negativity of the gallium scan after chemotherapy: 61 patients had negative and 13 patients had positive gallium scans.
  • In the gallium-positive group, 84.6% of the patients had recurrent disease and 61.5% were alive after intensive chemotherapy.
  • Disease-free survival differed significantly between patients with positive and patients with negative gallium scans at the end of chemotherapy (P<0.0001).
  • It is concluded that even if gallium scan is performed at the end of chemotherapy, it can predict outcome.
  • Alternative therapy may be required on the basis of gallium scan results obtained after treatment.
  • [MeSH-major] Citrates. Gallium. Hodgkin Disease / mortality. Hodgkin Disease / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11685490.001).
  • [ISSN] 0340-6997
  • [Journal-full-title] European journal of nuclear medicine
  • [ISO-abbreviation] Eur J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Citrates; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


17. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA: Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol; 2004 Jun 15;22(12):2303-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.
  • PURPOSE: To determine patterns of local-regional recurrence (LRR) and ipsilateral breast tumor recurrence (IBTR) among patients treated with breast conservation therapy after neoadjuvant chemotherapy.
  • PATIENTS AND METHODS: Between 1987 and 2000, 340 cases of breast cancer were treated with neoadjuvant chemotherapy followed by conservative surgery and radiation therapy.
  • Clinical stage at diagnosis (according to the 2003 American Joint Committee on Cancer system) was I in 4%, II in 58%, and III in 38% of patients.
  • RESULTS: At a median follow-up period of 60 months (range, 10 to 180 months), 29 patients had developed LRR, 16 of which were IBTRs.
  • Variables that positively correlated with IBTR and LRR were clinical N2 or N3 disease, pathologic residual tumor larger than 2 cm, a multifocal pattern of residual disease, and lymphovascular space invasion in the specimen.
  • CONCLUSION: Breast conservation therapy after neoadjuvant chemotherapy results in acceptably low rates of LRR and IBTR in appropriately selected patients, even those with T3 or T4 disease.
  • Advanced nodal involvement at diagnosis, residual tumor larger than 2 cm, multifocal residual disease, and lymphovascular space invasion predict higher rates of LRR and IBTR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / therapy. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Mastectomy, Segmental. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15197191.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


18. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E: High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma; 2006 Aug;47(8):1545-52
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
  • Although high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL), more than 50% of patients will experience relapse following ASCT.
  • High-dose sequential chemotherapy (HDSC) can intensify the conventional salvage treatment and improve the outcome of ASCT by maximal debulking of the tumor load with the use of non-cross resistant drugs, each at their maximal tolerated doses.
  • We conducted a phase II study in 40 patients with relapsed/refractory HD (n = 18) and NHL (n = 22) using HDSC followed by ASCT.
  • Only patients sensitive to salvage chemotherapy were eligible for the protocol, consisting of three phases.
  • Phase II consisted of etoposide (2 g/m2).
  • Eleven out of nineteen patients with B-cell lymphoma received rituximab.
  • Treatment-related mortality rate at day +100 was 2.5% (n = 1).
  • The estimated 4-year PFS and overall survival (OS) were 72.2% and 47.6% in HD patients and 70.3% and 69.4% in NHL patients, respectively.
  • Factors predicting OS were response to conventional salvage therapy and stage prior to salvage therapy.
  • Three prognostic subgroups were defined according to the score determined by stage prior to initiation of salvage chemotherapy, remission duration prior to salvage (refractory/early relapse vs. late relapse) and response to salvage.
  • In conclusion, HDSC followed by ASCT is an effective salvage therapy with acceptable toxicity, allowing further consolidation of response attained by conventional salvage therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / therapy. Peripheral Blood Stem Cell Transplantation / methods. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Etoposide / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Melphalan / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Remission Induction. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966265.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; Q41OR9510P / Melphalan
  •  go-up   go-down


19. Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL: Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys; 2002 Jul 15;53(4):880-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
  • PURPOSE: To compare the pathologic factors associated with postmastectomy locoregional recurrence (LRR) in breast cancer patients not receiving radiation who were treated with neoadjuvant chemotherapy (NEO) vs. adjuvant chemotherapy (ADJ).
  • METHODS AND MATERIALS: We retrospectively analyzed the rates of LRR of subsets of women treated in prospective trials who underwent mastectomy and received chemotherapy but not radiation.
  • These trials were designed to answer chemotherapy questions.
  • In the NEO group, 55% had clinical Stage IIIA or higher vs. 9% in the ADJ group (p <0.001, chi-square test).
  • RESULTS: Despite the more advanced clinical stage in the NEO group, the pathologic size of the primary tumor and the number of positive lymph nodes (+LNs) were significantly less in the NEO group than in the ADJ group (p <0.001 for both comparisons).
  • Most failures in this NEO subgroup had clinical Stage III disease.
  • In a subset of NEO and ADJ patients matched for clinical stage, no significant differences were found in the rates of LRR according to primary tumor size and number of +LNs when these variables were analyzed independently.
  • CONCLUSION: The rates of postmastectomy LRR for any pathologic tumor size are higher for patients treated with initial chemotherapy than for patients treated with initial surgery.
  • Radiotherapy should be offered to all patients with > or =4 +LNs, tumor size >5 cm, or clinical Stage IIIA or greater disease, regardless of whether they receive neoadjuvant or postoperative chemotherapy.
  • The information assessing LRR rates in patients with clinical Stage II disease who receive neoadjuvant chemotherapy, particularly if 1-3 lymph nodes remain pathologically involved, is insufficient to determine whether these patients should receive radiotherapy.
  • [MeSH-major] Breast Neoplasms / surgery. Chemotherapy, Adjuvant. Lymph Nodes / pathology. Lymphatic Metastasis
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Humans. Mastectomy. Middle Aged. Recurrence. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):850-1; author reply 851 [12573777.001]
  • (PMID = 12095553.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / T32CA77050
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


20. Kovács AF, Mose S, Böttcher HD, Bitter K: Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol; 2005 Jan;181(1):26-34
Hazardous Substances Data Bank. SODIUM THIOSULFATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
  • BACKGROUND: To examine the feasibility and efficacy of weekly docetaxel with concurrent radiation as postoperative treatment in a multimodality approach to oral and oropharyngeal cancer.
  • PATIENTS AND METHODS: 94 patients (Table 1) with primary resectable squamous cell carcinoma of the oral cavity and oropharynx (UICC stage I 14%, II 15%, III 18%, IV 53%; Table 2) were treated with a multimodality therapy program consisting of neoadjuvant intra-arterial high-dose chemotherapy (cisplatin 150 mg/m(2) with parallel systemic sodium thiosulfate 9 g/m(2) for neutralization), followed by surgery of the primary and neck, and postoperative concurrent radiation and chemotherapy with weekly docetaxel (20-30 mg/m(2); Table 3).
  • RESULTS: At a median follow-up of 4 years, the 5-year survival rate for all 94 patients was 80%, and disease-free survival was 73% (Figures 1 and 2).
  • Among patients with advanced disease (stage III and IV), survival was 83 and 59%, respectively (Figure 4).
  • CONCLUSIONS: Concurrent radiation and chemotherapy with weekly docetaxel is a feasible postoperative treatment in a multimodality approach to oral and oropharyngeal cancer, resulting in high overall and disease-free survival.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Radiotherapy, Adjuvant. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Feasibility Studies. Female. Follow-Up Studies. Head / pathology. Humans. Infusions, Intravenous. Injections, Intra-Arterial. Male. Middle Aged. Neck / pathology. Neck Dissection. Neoadjuvant Therapy. Neoplasm Staging. Postoperative Care. Radiotherapy Dosage. Survival Analysis. Thiosulfates / administration & dosage. Thiosulfates / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660190.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 0 / Thiosulfates; 15H5577CQD / docetaxel; HX1032V43M / sodium thiosulfate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Schaefer PL, Marks RS, Mahoney MR, Sloan JA, Bauman MD, Tazelaar HD, Kugler JW, Mailliard JA, Ebbert LP, Wiesenfeld M: Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers. Am J Clin Oncol; 2003 Jun;26(3):236-40
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
  • A randomized two-stage, phase II study was conducted to assess the antitumor activity of two different schedules of topotecan in the treatment of extensive-stage small-cell lung cancer (SCLC) in chemotherapy-naive patients.
  • Median times to progression for the daily and continuous-infusion schedules are 5 months (90% CI: 4.4-7.2) and 2 months (90% CI: 1.1-2.1), respectively.
  • Fifty percent (30/60) of patients received second-line therapy with etoposide and cisplatin.
  • Forty-three percent (13/30) of patients who received second-line therapy achieved a confirmed response.
  • Topotecan showed significant activity in the treatment of extensive stage SCLC when administered as a brief daily IV repeated every 3 weeks.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Topotecan / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12796591.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849; United States / NCI NIH HHS / CA / CA60276
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 7M7YKX2N15 / Topotecan; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Lester EP, Petroni GR, Barcos M, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E 3rd, Peterson BA: Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856. Cancer Invest; 2001;19(5):447-58
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856.
  • Successful treatment of advanced-stage Hodgkin's disease (HD) may critically depend on dose intensity.
  • Because mechlorethamine, Oncovin, procarbazine, and prednisone (MOPP), and Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) are not suitable for major dose escalation, we evaluated the activity and toxicity of combined cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) in advanced HD, here used at conventional dose intensity, as a preparatory study prior to using this regimen at higher dose intensity.
  • All had advanced HD with no prior chemotherapy with 46% stage IV, 63% with B symptoms, and 57% with bulky disease (> 5 cm).
  • Toxicity was generally acceptable and primarily hematologic, with neutrophils < 500 in 63% of cohort I and 90% of cohort II, and platelets < 25,000 in 7% of cohort I and 8% of cohort II.
  • In cohort II, 77% achieved a CR with 6-8 cycles of CHOPE alone.
  • FFS was 76% in cohort I and 59% in cohort II, with a median follow-up of 8.2 and 5.7 years, respectively.
  • CHOPE, at conventional dose intensity as used here, is an effective first-line regimen for the treatment of advanced-stage HD and may warrant evaluation using higher doses of cyclophosphamide and etoposide with granulocyte colony stimulating factor (G-CSF) support.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11458812.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA47545; United States / NCI NIH HHS / CA / CA47555
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  •  go-up   go-down


23. Coleman M, Kaufmann T, Nisce LZ, Leonard JP: Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1235-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of nonlaparotomized (clinical) stage I and II Hodgkin's disease patients by extended field and splenic irradiation.
  • PURPOSE: At the New York Presbyterian Hospital-Cornell Medical Center, patients with unequivocal clinical stage I and IIA Hodgkin's disease (HD) have been treated with mantle, splenic, and extended field radiation therapy (EFRT) (without surgical staging).
  • METHODS AND MATERIALS: During the period 1971 to 1994, 94 patients with clinically staged HD, with favorable prognostic factors, were retrospectively reviewed.
  • Patients with pathological or equivocal staging, "B" symptoms, bulk disease, history of previous chemotherapy, and/or Stage III or IV disease were excluded from our analysis.
  • There were 27 Stage IA and 67 Stage IIA patients.
  • The median time to relapse was 38 months; mean time 42. 3 months.
  • All patients are alive, well and free of disease, including nine who received subsequent chemotherapy and one who underwent autotransplantation.
  • CONCLUSIONS: Careful clinical staging of early, asymptomatic HD patients treated with mantle, splenic, and EFRT may obviate the need for exploratory laparotomy.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Spleen
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10725636.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 07968
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


24. Molina JR, Jett JR, Foster N, Lair BS, Carroll TJ, Tazelaar HD, Hillman S, Mailliard JA, Bernath AM Jr, Nikcevich D: Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. Am J Clin Oncol; 2006 Jun;29(3):246-51
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
  • OBJECTIVE: To determine the efficacy and toxicity of oral topotecan and paclitaxel in untreated patients with extensive stage small cell lung cancer (SCLC).
  • Subcutaneous G-CSF at a dose of 5 microg/kg was then given 24 to 48 hours after the last dose of chemotherapy and daily for 10 days.
  • A median of 5 treatment cycles was given, with a range of 1 to 7 cycles.
  • Seventeen (45%) patients received at least 6 cycles of treatment.
  • Two grade 5 treatment-related evens were seen.
  • The median time to progression was 5.0 months (95% CI: 3.8-6.6 months), with a 1-year progression-free rate of 5.8% (95% CI: 1.5-22.2%) and a 2-year progression-free rate of 2.9% (95% CI: 0.4-19.9%).
  • CONCLUSION: This regimen has shown similar antitumor activity to that achieved with standard therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Paclitaxel / administration & dosage. Survival Analysis. Topotecan / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755177.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-35629; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-CA-63849
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Córdoba S, Romero J, De la Torre A, Valcárcel F, Magallón R, Regueiro CA, García-Berrocal MI: Early stage infradiaphragmatic Hodgkin's disease: results of radiotherapy and review of the literature. Radiother Oncol; 2003 Jun;67(3):259-63
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage infradiaphragmatic Hodgkin's disease: results of radiotherapy and review of the literature.
  • PURPOSE: To assess the impact of modality therapy on long-term outcome for infradiaphragmatic Hodgkin's disease (IDHD).
  • METHODS AND MATERIALS: During the period 1965-1997, 847 patients with early stage Hodgkin's disease (HD) were evaluated and treated at our institution, 20 of them had IDHD (2.4%).
  • Patients characteristics: stage I, nine patients (five pathological stage (PS), and four clinical stage (CS)) and stage II: 11 patients (six PS and five CS).
  • Two modalities of treatment were used: combined modality (CMT), consisting of chemotherapy followed by extended field radiotherapy or radiotherapy alone (XRT).
  • All patients with CS or PS II, except in one case, were treated with CMT.
  • RESULTS: The relapse rate after initial treatment was 30%.
  • Ten-year disease free survival (DFS) and 10-year cause-specific survival were 60% and 92%, respectively.
  • There was a non-significant trend to a better DFS for the CMT group of patients (76% vs. 35% for the whole series and 100% vs. 24% for stage I patients).
  • CONCLUSIONS: In our experience, inguino-femoral stage I patients have a high relapse rate after XRT; consequently, CMT consisting of chemotherapy plus involved field radiotherapy should be recommended for early stage HD confined below diaphragm.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Diaphragm. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12865173.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 24
  •  go-up   go-down


26. Perez EA, Geoffroy FJ, Hillman S, Johnson EA, Farr GH Jr, Tazelarr HD, Hatfield AK, Krook JE, Maillard JA, Levitt R, Marks RS: Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Lung Cancer; 2004 Jun;44(3):347-53
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer.
  • BACKGROUND: This study evaluated the activity and tolerance for the combination of oral etoposide and paclitaxel as first-line therapy for patients with extensive SCLC.
  • A cycle of chemotherapy consisted of oral etoposide administered as 50 mg BID on days 1 through 10 and paclitaxel administered as 150 mg/m(2) IV (3 h infusion) along with the first dose of etoposide on day 10.
  • Patients were assessed for response to therapy (regression, stable disease, progression), survival, time to disease progression, and toxicity.
  • Among the 55 patients, there were six with complete regression of disease, 18 with partial regression, 11 with regression, five with stable disease, and 15 with progressive disease, yielding an overall response rate of 63.6% (95% confidence interval, 50.0-76.0%).
  • The median time to disease progression was 5.8 months.
  • The combination of oral etoposide and paclitaxel demonstrated significant efficacy as first-line therapy for extensive SCLC, with an overall response rate of 63.6% for 55 evaluable patients.
  • In addition, the treatment was well tolerated with no unexpected toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Small Cell / drug therapy. Etoposide / administration & dosage. Lung Neoplasms / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Drug Synergism. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15140548.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35272; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849; United States / NCI NIH HHS / CA / CA35269
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Dühmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Rühl U, Müller RP, Lukas P, Atzinger A, Paulus U, Lathan B, Rüffer U, Sieber M, Wolf J, Engert A, Georgii A, Staar S, Herrmann R, Beykirch M, Kirchner H, Emminger A, Greil R, Fritsch E, Koch P, Drochtert A, Brosteanu O, Hasenclever D, Loeffler M, Diehl V: Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol; 2001 Jun 01;19(11):2905-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
  • PURPOSE: To show that radiotherapy (RT) dose to the noninvolved extended field (EF) can be reduced without loss of efficacy in patients with early-stage Hodgkin's disease (HD).
  • PATIENTS AND METHODS: During 1988 to 1994, pathologically staged patients with stage I or II disease who were without risk factors (large mediastinal mass, extranodal lesions, massive splenic disease, elevated erythrocyte sedimentation rate, or three or more involved areas) were recruited from various centers.
  • All patients received 40 Gy total fractionated dose to the involved field areas but were randomly assigned to receive either 40 Gy (arm A) or 30 Gy (arm B) total fractionated dose for the clinically noninvolved EF.
  • No chemotherapy was given.
  • The most common causes of death (n = 27) were cardiorespiratory disease/pulmonary embolisms (seven), second malignancy (six), and HD (five).
  • CONCLUSION: EF-RT alone attains good survival rates in favorable early-stage HD.
  • The 30-Gy dose is adequate for clinically noninvolved areas.
  • Relapse patterns suggest that systemic therapy can reduce the 20% long-term relapse rate.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Dose Fractionation. Female. Humans. Male. Middle Aged. Patient Compliance. Prognosis. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11387364.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, Dörken B, Hossfeld DK, Diehl V, Engert A, Participating Centers: Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol; 2002 Oct;13(10):1628-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
  • BACKGROUND: An important variable affecting outcome in relapsed and refractory Hodgkin's disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume before high-dose chemotherapy (HDCT) and autologous stem cell transplantation.
  • Currently, the optimal salvage chemotherapy regimen for these patients is unclear.
  • Since dexamethasone/cisplatin/cytarabine (DHAP) given at 3-4 week intervals has been shown to be very effective in patients with relapsed aggressive non-Hodgkin's lymphoma, we evaluated this regimen given at a median of 16-day intervals in patients with relapsed and refractory HD.
  • PATIENTS AND METHODS: Patients with relapsed or refractory HD were treated with two cycles of DHAP [dexamethasone 40 mg intravenously (i.v.) day 1-4, cisplatin 100 mg/m(2) i.v. as 24-h continuous infusion day 1, and cytarabine 2 g/m(2) i.v.
  • Forty-two percent of the patients had late relapse, 29% early relapse, 12% multiple relapse and 16% primary progressive/refractory disease.
  • The RRs for patients with late, early, multiple and progressive HD were 91%, 93%, 92% and 65%, respectively.
  • Using the chi-square test for independence, remission status (relapsed HD versus progressive HD) and stage at relapse (stage I/II versus stage III/IV) were significant factors for response to DHAP.
  • Neither severe infections nor treatment-related deaths occurred.
  • CONCLUSIONS: A brief tumor-reducing program with two cycles of DHAP given in short intervals supported by G-CSF is effective and well-tolerated in patients with relapsed and refractory HD.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12377653.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailänder V, Oertel J, Diehl V, Engert A, German Hodgkin's Lymphoma Study Group: Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol; 2004 Jun 15;22(12):2424-9
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group.
  • PURPOSE: To investigate a new effective, nonleukemogenic polychemotherapy regimen, BAGCOPP (bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, gemcitabine) in a phase I/II dose-escalation study in patients with advanced-stage Hodgkin' s disease (HD).
  • A total of eight patients developed lung toxicity, mainly pneumonitis (six of eight), which led to the termination of the study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Etoposide / administration & dosage. Hodgkin Disease / diet therapy. Lung Diseases / chemically induced
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15136597.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; VB0R961HZT / Prednisone
  •  go-up   go-down


30. Kochbati L, Boussen H, Benna F, Belhaj Ali Z, Gammoudi A, Bouaouina N, Besbes M, Ghilen L, Rahal K, Maalej M: [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz]. Cancer Radiother; 2003 Oct;7(5):302-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
  • [Transliterated title] Tumeurs secondaires après traitement pour maladie de Hodgkin en Tunisie. Etude rétrospective à propos de 26 cas observés à l'institut Salah-Azaïz.
  • PURPOSE: To collect second cancers in patients treated for Hodgkin disease (HD) during adolescence and young adulthood at Salah Azaïz Institute of Tunis.
  • METHODS AND PATIENTS: We consider as second cancer all tumours other than HD observed in patients after treatment for HD.
  • RESULTS: Twenty-five patients among 614 treated for HD between 1975 and 1991 developed 26 secondary tumours (4.2%).
  • Mean age at the diagnosis of HD was 32.5 years (12-56).
  • HD was stage II (eight cases), stage III (14) and stage IV in three.
  • The first treatment was combined chemotherapy and radiotherapy in 22 cases and only chemotherapy in three cases (stage IV).
  • Mean dose was 41.3 Gy (2 Gy/fraction in 21 and 3.3 in one).
  • Chemotherapy was MOPP (13), MOPP and vinblastine (four), MOPP-ABVD (five), ABVD (two) and vinblastine only in one.
  • There was five acute myeloid leukaemia, two digestive non-Hodgkin lymphomas, five nodal high-grade lymphomas, three breast cancers (one in man associated with thyroid cancer), five lung cancers (three non-small cell and two of small cell type), two gastric tumours and one rectal cancer, one synovialosarcoma of the knee and one malignant Schwannoma of the neck.
  • CONCLUSION: Second cancer risk after treatment for HD is not low.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Child. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Incidence. Male. Mechlorethamine / adverse effects. Middle Aged. Prednisone / adverse effects. Procarbazine / adverse effects. Retrospective Studies. Risk Factors. Tunisia / epidemiology. Vinblastine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14522350.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


31. Busetto M, Sotti G, Zorat P, Salvagno L, Dal Fior S, Gaion F, Soraru M, Gruppo Veneto Linfomi, Radiotherapy and Medical Oncology sections, Associazione Italiana di Radioterapia Oncologica, Triveneto section: A consensus protocol: Image-improved therapeutic guidelines for limited adult Hodgkin's disease. Tumori; 2004 Nov-Dec;90(6):630-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A consensus protocol: Image-improved therapeutic guidelines for limited adult Hodgkin's disease.
  • Hodgkin's disease (HD) has greatly benefited from new technologies in terms of less invasive and more accurate staging as well as improved overall and relapse-free survival.
  • However, the likelihood of late adverse effects of treatment, including second tumors, has increased due to the longer survival of patients with HD.
  • Today's trend is to aim at minimal therapeutic exposure while guaranteeing lower therapy-related morbidity.
  • This encourages new research efforts but also leads to less uniformity in treatments, as observed in the Veneto Region in Italy.
  • The Gruppo Veneto Linfomi, composed of representatives of Radiotherapy and Oncology Departments of the Veneto Region, has been analyzing this problem and proposing therapy guidelines since 1995.
  • A set of 10 prognostic factors has been developed to identify three prognostic groups: highly favorable (HF) are patients up to 40 years of age presenting with stage I disease involving only one site of disease with a maximum tumor diameter (TD) of 5 cm and no adverse factors.
  • In this group only mantle field irradiation is recommended if the disease is located in the neck or above, inverted-Y irradiation is recommended for distal subdiaphragmatic lesions, and subtotal nodal irradiation in all other cases.
  • Favorable (F) cases are patients in stage I with a TD greater than 5 cm and smaller than 10 cm or stage II, up to three sites of disease and negative prognostic factors for systemic disease.
  • All other patients are included in the "not favorable" (NF) group at Ann Arbor stage I or II with any adverse prognostic factor.
  • For the latter two groups, chemotherapy with the ABVD or Stanford V regimen precedes involved-field radiotherapy to sites with a TD of at least 5 cm.
  • The total irradiation dose is determined by local disease extent and level of response to chemotherapy.
  • Images on which the radiation fields are drawn serve as an important reference to improve the homogeneity of treatments.
  • This protocol includes a list of adverse treatment effects (chemo- and/or radiotherapy) together with follow-up guidelines for the early detection of secondary cancers in previously irradiated patients.
  • [MeSH-major] Hodgkin Disease / pathology. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adult. Breast Neoplasms / etiology. Clinical Protocols. Consensus. Female. Humans. Italy. Neoplasm Staging. Prognosis. Radiotherapy / adverse effects. Risk Assessment. Risk Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762371.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Guideline; Journal Article; Practice Guideline
  • [Publication-country] United States
  •  go-up   go-down


32. Economopoulos T, Fountzilas G, Dimopoulos MA, Papageorgiou S, Xiros N, Kalantzis D, Dervenoulas J, Raptis S: Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study. Eur J Haematol; 2003 Oct;71(4):257-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study.
  • The purpose of this prospective phase II trial was to investigate the safety and efficacy of a modified baseline BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen in the treatment of intermediate and advanced stage Hodgkin's disease (HD).
  • From October 1997 to November 2001, 51 consecutive, previously untreated patients with stage IIA (bulky), IIB, III, and IV disease were treated with a modified baseline BEACOPP regimen with the etoposide administered i.v. on day 1 and orally at a dose of 100 mg/m2, on days 2 and 3.
  • Each patient was scheduled to receive eight courses of BEACOPP with consolidation radiotherapy to bulky (> or =5 cm) or residual disease.
  • There were 25 males and 26 females with a median age of 32 yr (16-65 yr); 80.3% of the patients had nodular sclerosis HD, 41% had bulky disease (> or =5 cm), 10 were in stage IIA (bulky > or =10 cm), 15 in stage IIB, 19 in stage III, and seven in stage IV.
  • No significant difference in overall response rate was observed between patients with: (i) 0-2 vs. > or =3 negative prognostic factors, (ii) in stage II vs. stages III/IV, LDH level, and bulky disease.
  • With a median follow up period of 39.5 months, actuarial 3-yr survival rate is 82% and time to progression rate 72.5%.
  • Treatment with this combination was well tolerated.
  • The results of the present study demonstrate that the modified baseline BEACOPP regimen with radiotherapy used in our patients was well tolerated and effective therapy for intermediate and advanced stage HD.
  • Further follow up time is required to evaluate long-term toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Prednisone / therapeutic use. Procarbazine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12950234.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; BEACOPP protocol
  •  go-up   go-down


33. Alexandrescu DT, Karri S, Wiernik PH, Dutcher JP: Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease. Leuk Lymphoma; 2006 Apr;47(4):641-56
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease.
  • Advanced-stage or relapsed/refractory Hodgkin's disease (HD) has a poor prognosis despite aggressive chemotherapy regimens and the use of high-dose therapy with autologous stem cell support.
  • Mitoxantrone, vinblastine and CCNU (lomustine) (MVC) combines the most effective chemotherapeutic agents of previous regimens for poor prognosis HD, and eliminates marginally active agents with unnecessary toxicities, such as bleomycin and dacarbazine.
  • Sixty-eight patients with HD (23 newly diagnosed and 45 with relapsed/refractory disease, one patient treated both de novo and years later in relapse) were treated with the MVC regimen (mitoxantrone 8 mg/m(2)/day i.v. days 1 - 3; vinblastine 8 m/m(2)/day days 1 and 22; and CCNU (lomustine) 100 mg/m(2) on day 1, repeated at 6 - 8 weeks) in a single-arm Phase II study.
  • All patients responded to treatment in the newly diagnosed group (overall response = 100%).
  • MVC regimen for HD is highly active, for both de novo and relapsed/refractory disease, with high response rates and survival that compare favourably with the results obtained by high-dose therapy with stem-cell transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lomustine / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / therapeutic use. Vinblastine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690523.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA14958; United States / NCI NIH HHS / CA / P30CA13330
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5V9KLZ54CY / Vinblastine; 7BRF0Z81KG / Lomustine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


34. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F: Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma; 2001 May;41(5-6):535-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome.
  • We report the frequency, presenting characteristics, progression-free survival, event-free survival, overall survival and AIDS-free survival of patients with previously untreated Hodgkin's disease (HD) in the setting of infection by human immunodeficiency virus (HIV).
  • Anderson Cancer Center between July 1985 and August 1999 with HD and HIV infection.
  • All available records were reviewed to determine presentation, clinical characteristics, treatment outcome, progression-free survival and overall survival.
  • We identified 887 patients with HD and 3,500 with Non-Hodgkin's Lymphoma (NHL).
  • The ratio of NHL to HD in HIV-negative versus HIV-positive patients was 3.9 versus 6.9, respectively.
  • There were 14 HIV-positive patients with HD and 97 with NHL.
  • The median age of the HIV-positive HD patients was 33 years, and 13 were male.
  • Three patients had Acquired Immune Deficiency syndrome (AIDS) at the time of HD diagnosis, and seven had B-symptoms.
  • Ann Arbor stage was I in one, II in three, III in four and IV in six patients.
  • Mixed cellularity histology was seen in eight, bone marrow involvement in five and extranodal disease in seven patients.
  • All patients received some antiretroviral therapy, but it was variable over the years.
  • Six patients died of complications arising from HIV infection, including one patient who had preexisting AIDS at HD presentation.
  • Two patients died of HD, without developing other conditions diagnostic of AIDS.
  • We conclude that in our referral patient population HIV infection is associated with preferential development of NHL rather than HD, which appears curable with standard treatment regimens.
  • Since HIV-related deaths exceed those caused by HD, future investigation should focus on integration of chemotherapy and highly active antiretroviral therapy.
  • [MeSH-major] Hodgkin Disease / virology. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Actuarial Analysis. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antiviral Agents / administration & dosage. Female. Humans. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378571.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


35. Fitoussi, Eghbali H, Tchen N, Berjon JP, Soubeyran P, Hoerni B: Semen analysis and cryoconservation before treatment in Hodgkin's disease. Ann Oncol; 2000 Jun;11(6):679-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semen analysis and cryoconservation before treatment in Hodgkin's disease.
  • BACKGROUND: The prophylaxis of the late effects of chemotherapy and radiotherapy has become one of the major concerns in the management of Hodgkin's disease (HD).
  • PATIENTS AND METHODS: To evaluate the semen quality of patients with HD and the outcome of insemination, we reviewed spermograms of patients who underwent SP before any treatment.
  • 2) HD of any stage;.
  • 3) informed about male sterility after HD treatment;.
  • All patients underwent an initial chemotherapy.
  • Pretherapeutic staging of HD revealed 38 stage I (40%), 38 II (38%), 14 III (15%) and 4 IV (4%).
  • The analysis of semen quality and spermatozoid amount according to various parameters failed to find a correlation with stage, B symptoms, age, or biologic data (LDH, WBC, platelets, ESR).
  • CONCLUSIONS: The low rate of success with cryopreserved semen in these cases suggests the need for a more careful design of non-toxic chemotherapy regimens in combined modality treatment.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10942055.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Lee JK, Tsai SC, Ho YJ, Changlai SP, Kao CH: Technetium-99m tetrofosmin scintigraphy for detecting malignant lymphoma. Anticancer Res; 2001 Mar-Apr;21(2B):1509-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Technetium-99m tetrofosmin scintigraphy for detecting malignant lymphoma.
  • In the study, before any chemotherapy, 50 patients with malignant lymphoma underwent Tc-TF scintigraphy, which was performed 10 minutes after intravenous injection of 20 mCt Tc-TF.
  • Tc-TF scintigraphy detected malignant lymphoma in 44 (88%) patients.
  • However, there were no significant differences in the incidences of positive and negative Tc-TF scintigraphic results between female versus male patients, HD versus NHL patients, stage I-II versus stage III-IV patients, age > 40 years versus < or = 40 years patients and patients with B symptoms false-negative results occurred in 4 (8%) infradiaphragmatic malignant lymphoma.
  • We conclude patients with that Tc-TF scintigraphy appears suitable for detecting malignant lymphoma, especially supradiaphragmatic lesions.
  • [MeSH-major] Lymphoma / diagnosis. Organophosphorus Compounds. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11396241.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


37. Renedo RJ, Sousa MM, Pérez SF, Zabalbeascoa JR, Carro LP: Avascular necrosis of the femoral head in patients with Hodgkin's disease. Hip Int; 2010 Oct-Dec;20(4):473-81
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avascular necrosis of the femoral head in patients with Hodgkin's disease.
  • Avascular necrosis of the femoral head (ANFH) is a rare complication that may occur in patients diagnosed with Hodgkin's Disease (HD), as a result of treatment.
  • A review was made of 315 cases of HD treated with systemic chemotherapy associated with high doses of steroids and radiation therapy and 18 patients (5.71%) were found to have developed ANFH during treatment.
  • The mean follow-up time for chemotherapy was 40 months (range 20-110 months) with an average dose of prednisone of 8.45 g (range 3.20 - 18.50).
  • In 8 cases (44.44%) forage associated with IES was performed as the initial treatment option and 6 of these cases were found to be in Ficat stage II (75%), 1 was found to be in stage III (12.55%) and another in stage IV (12.5%).
  • In 2 cases, the central decompression technique was used (Simple Forage); both were in Ficat stage II.
  • In the other 8 cases, a total hip arthroplasty (THA) was chosen as the initial treatment option, with 3 of these patients in Ficat stage III and 5 in Ficat stage IV.
  • The clinical outcomes (time to postoperative pain, time to radiological failure, and time to arthroplasty from the forage) following surgical management using the forage-biopsy technique with and without internal electrostimulation (IES) were recorded.
  • We observed that treatment with Forage + IES was better than simple Forage in stages below III in patients with Hodgkin's Disease.
  • We considered that in Ficat stage III and IV arthroplasty (THA) was the better option.
  • [MeSH-major] Femur Head Necrosis / pathology. Hodgkin Disease / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arthroplasty, Replacement, Hip. Decompression, Surgical. Electric Stimulation Therapy. Female. Glucocorticoids / adverse effects. Humans. Male. Middle Aged. Prednisone / adverse effects. Radiotherapy, Adjuvant. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157752.001).
  • [ISSN] 1724-6067
  • [Journal-full-title] Hip international : the journal of clinical and experimental research on hip pathology and therapy
  • [ISO-abbreviation] Hip Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


38. Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents]. Ai Zheng; 2007 Dec;26(12):1339-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
  • BACKGROUND & OBJECTIVE: Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) and often involves bone marrow and central nerve system.
  • The efficacy of CHOP regimen on Burkitt's lymphoma is poor.
  • The optimal chemotherapy regimen needs to be investigated.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in children and adolescents, and observe the survival status.
  • 2006, 31 untreated Burkitt's lymphoma patients aged less than 20 were enrolled.
  • According to St Jude staging system, 1 (3.2%) was at stage I, 6 (19.4%) at stage II, 8 (25.8%) at stage III, 16 (51.6%) at stage IV; 24 (77.4%) were at stage III/IV.
  • According to clinical stage, lactate dehydrogenase (LDH) level and treatment response, these patients were divided into low, moderate and high risk groups.
  • They received modified B-NHL-BFM-90 protocol: cytotoxic drugs such as cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesin, dexamethasone, cytarabinec/HD-cytarabine and intrathecal injection.
  • Of the 30 patients, 25 (83.3%) achieved complete remission (CR), 3 (10.0%) achieved partial remission (PR), 2 (6.7%) had progressive disease (PD)û 1 had tumor relapse.
  • Grade 3-4 myelosuppression occurred in most patients and were recovered by active support care and did not affect next course of chemotherapy.
  • At a median follow-up of 33 months (range, 3-98 months), the 3-year event-free survival (EFS) rate was 86.0% for all patients, with 100% for stage I/II patients and 82.1% for stage III/IV patients, 100% for low risk group, 92.0% for moderate risk group, and 70.0% for high risk group.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol can improve the responses and survival of Burkitt's lymphoma in Chinese children and adolescents, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Staging. Remission Induction. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076797.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


39. Petera J, Macharová H, Pohanková R, Malír A, Coupek P, Konecný M, Patera J, Pecina J, Drbal J, Koukalová H, Vásová I: Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute. Neoplasma; 2000;47(2):129-32
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
  • Radiotherapy and chemotherapy, alone or in combination, are curative treatment methods in early stages of Hodgkin's disease (HD).
  • The choice of treatment depends on the stage of the disease, histological type and localization of the tumor, as well as on other prognostic factors.
  • A retrospective study was conducted including 145 patients with clinical Stages I and II of HD according to Ann Arbor classification, all treated in the Masaryk Memorial Cancer Institute in Brno during the years 1985 through 1994.
  • 41 patients were diagnosed with Stage IA tumor, 1 patient with Stage IB, 75 patients with Stage IIA and 28 with Stage IIB disease.
  • The histological types of the disease were lymphocyte predominant in 23 patients, nodular sclerosis in 49 patients, mixed cellularity in 65 cases and lymphocyte depletion in 8 cases.
  • 39 patients were treated with combination of radiotherapy and chemotherapy.
  • 15 patients were given chemotherapy alone, 7 patients from this group experienced a relapse.
  • The five-year survival was 81% in patients with Stages IA and IIA disease, 65% in Stages IB and IIB disease.
  • Radiotherapy remains the curative method of choice in highly selected group of patients with early stages of Hodgkin's disease.
  • The results of radiotherapy alone are unsatisfactory in unselected clinical Stage I--II patients because of the presence of patients with adverse prognostic factors, particularly B symptomatology, mixed cellularity/lymphocyte depletion histology, higher age.
  • These patients are candidates for combined treatment.
  • Modern equipment and meticulous treatment are conditions crucial for the outcome of curative radiotherapy in patients with Hodgkin's disease.
  • Combination chemotherapy is very effective in the treatment of relapse following the primary radiotherapy.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10985481.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SLOVAKIA
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COPP protocol; MOPP protocol; VBA protocol
  •  go-up   go-down


40. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK: Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol; 2006 Sep 1;24(25):4116-22
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease.
  • PURPOSE: To estimate the clinical benefits and cost effectiveness of computed tomography (CT) in the follow-up of patients with complete response (CR) after treatment for Hodgkin's disease (HD).
  • PATIENTS AND METHODS: We developed a decision-analytic model to evaluate follow-up strategies for two hypothetical cohorts of 25-year-old patients with stage I-II or stage III-IV HD, treated with doxorubicin, bleomycin, vinblastine, and dacarbazine-based chemotherapy with or without radiation therapy, respectively.
  • With adjustments for quality of life, we found a decrement in quality-adjusted life expectancy for early-stage patients followed with CT compared with non-CT modalities.
  • For advanced-stage patients, annual CT for 5 years is associated with a very small quality-adjusted survival gain over non-CT follow-up with an incremental cost-effectiveness ratio of 9,042,300 dollars/QALY.
  • CONCLUSION: Our analysis suggests that routine CT should not be used in the surveillance of asymptomatic patients in CR after treatment for HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Decision Support Techniques. Hodgkin Disease / economics. Hodgkin Disease / radiography. Population Surveillance / methods. Tomography, X-Ray Computed / economics
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Cost-Benefit Analysis. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Life Expectancy. Markov Chains. Neoplasm Staging. Predictive Value of Tests. Quality-Adjusted Life Years. Sensitivity and Specificity. Survival Analysis. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16943528.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 R25 CA57711-11
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin
  •  go-up   go-down


41. Staib L, Gottwald T, Lehnert T, Ruf G, Sturm J, Becker HD, Farthmann E, Herfarth C, Post S, Trede M, Beger HG: Sphincter-saving treatment in epidermoid anal cancer: cooperative analysis of 142 patients in five German university surgical centers. Int J Colorectal Dis; 2000 Nov;15(5-6):282-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter-saving treatment in epidermoid anal cancer: cooperative analysis of 142 patients in five German university surgical centers.
  • Five southern German university centers cooperated in comparing the effect of surgical vs. nonsurgical therapy strategies on survival and sphincter preservation in the treatment of anal cancer.
  • A standardized questionnaire was used to evaluate retrospectively (mean follow-up 30 months) treatment strategy and outcome (survival, colostomy rate, colostomy-free survival) in patients treated between 1987 and 1996.
  • Of the 142 patients 65% had squamous cell, 20% basaloid, 6% adeno-, and 1% undifferentiated carcinoma (8% histology not recorded); 9% were classified in UICC stage I, 37% in stage II, 25% in stage III, and 4% in stage IV (25% not recorded).
  • Primary treatment consisted of local excision (10%), excision plus radio- and/or chemotherapy (17%), radiotherapy (20%), radiochemotherapy (28%), or colostomy with or without resection, radiotherapy, and chemotherapy (23%).
  • We observed no difference between these treatment groups in overall (P = 0.43) or colostomy-free survival (P = 0.14, log-rank).
  • Mean overall survival (in months) was 42 in stage I, 38 in stage II, and 25 in stage III (P = 0.0013); mean colostomy-free survival was 36 in stage I, 26 in stage II, and 16 in stage III (P = 0.0021, log-rank).
  • Outcome was not significantly related to therapeutic strategy (surgery or radio-chemotherapy.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma / mortality. Carcinoma / surgery. Carcinoma / therapy. Clinical Trials as Topic. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multicenter Studies as Topic. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11151431.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Szelényi H, Kreuser ED, Keilholz U, Menssen HD, Keitel-Wittig C, Siehl J, Knauf W, Thiel E: Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma. Ann Oncol; 2001 Jan;12(1):105-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma.
  • BACKGROUND: Patients with advanced multiple myeloma (stage III or progressive myeloma) received the CAD protocol every three weeks: cyclophosphamide 200 mg/m2 i.v.
  • According to Durie-Salmon 44 patients were in stage III, 2 in stage II; 6 patients had renal insufficiency (stage B).
  • RESULTS: Remission rates were as follows: complete remission 4%, partial remission 70%, minimal change 11%, no change 11%, progressive disease 4%.
  • After an observation time of 14 months the median progression free interval for 33 patients not treated with subsequent high-dose chemotherapy with stem-cell support was more than 14 months.
  • Overall, treatment was well tolerated.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11249035.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


43. Shahar KH, Hunt KK, Thames HD, Ross MI, Perkins GH, Kuerer HM, Strom EA, McNeese MD, Meric F, Schechter NR, Sahin AA, Middleton LP, Buchholz TA: Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys; 2004 Jul 15;59(4):1074-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously shown that modified breast tangent fields can include most axillary Level I-II lymph nodes.
  • We separately analyzed the outcome for those initially treated with surgery (n = 265) and those receiving neoadjuvant chemotherapy (n = 74).
  • For the patients treated with neoadjuvant chemotherapy, the independent factors were clinical Stage III (rate, 48%, OR = 3.1, p = 0.03), more than one positive SLN (rate, 37-67%, OR = 4.8, p = 0.03), and LVSI (rate, 62%, OR = 8.1, p = 0.02).
  • CONCLUSION: It is reasonable to treat with modified tangents fields that include most axillary Level I-II nodes for patients with one positive SLN who do not undergo axillary dissection if drainage is seen on lymphoscintigraphy and no LVSI is present.
  • This approach is also reasonable for patients treated with neoadjuvant chemotherapy who have Stage II disease, no LVSI, and only one positive SLN.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla. Chemotherapy, Adjuvant. Clavicle. Humans. Lymph Node Excision. Lymphatic Irradiation. Middle Aged. Odds Ratio. Regression Analysis. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15234041.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I: ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant; 2006 Feb;37(3):277-82
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
  • From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT).
  • DLCL 49: HD 78.
  • Initial stage I:II:III:IV:unknown was 15:34:33:42:3.
  • Median prior chemotherapy cycles were six [<6 (17 patients), 6-8 (90 patients), >8 (20 patients)].
  • Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adult. Blood Component Removal / methods. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Methylprednisolone / administration & dosage. Recurrence. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400345.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


45. Chisesi T, Federico M, Levis A, Deliliers GL, Gobbi PG, Santini G, Luminari S, Linfomi MB, Intergruppo Italiano Linfomi: ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol; 2002;13 Suppl 1:102-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
  • BACKGROUND: Between January 1996 and April 2000, 355 patients with advanced Hodgkin's disease (HD) (stage II bulky disease, III and IV) were enrolled in a prospective, multicentre, randomised trial aimed at comparing the efficacy of two new promising regimens: Stanford V and MEC hybrid.
  • Radiotherapy was planned at the end of induction therapy on residual masses or on sites of previous bulky lesions.
  • RESULTS: After induction therapy a complete response (CR) was observed in 93, 89 and 74% of patients treated with MEC, ABVD and Stanford V, respectively, with a statistically significant difference (P = 0.013) between the arms.
  • Toxicity was comparable in the three treatment arms.
  • Notwithstanding the short follow-up, these results seem to be very impressive in defining the best standard treatment for HD for this subset of patients.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12078888.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone
  •  go-up   go-down


46. Potapov EV, Hennig F, Wagner FD, Volk HD, Sodian R, Hausmann H, Lehmkuhl HB, Hetzer R: Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure. Eur J Cardiothorac Surg; 2005 May;27(5):899-905
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: In patients with inotrope-dependent end-stage heart failure the timely application of the most suitable treatment, i.e. heart transplantation, implantation of a ventricular assist device or conservative treatment, is a key issue for therapeutic success.
  • METHODS: Seventy-six inotrope-dependent patients with end-stage heart failure were enrolled.
  • The patients were retrospectively divided into groups with regard to the following end-points: Group I-deterioration into cardiogenic shock after an initially stable clinical course (n=26); Group II-stable clinical course without deterioration into cardiogenic (n=41); Group III-weaning from inotropic support (n=9).
  • RESULTS: One day before cardiogenic shock occurred, BNP, NT-proBNP and E-selectin were significantly elevated in group I compared with group II.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers / blood. C-Reactive Protein / analysis. Dobutamine / administration & dosage. Dobutamine / therapeutic use. Dopamine / administration & dosage. Dopamine / therapeutic use. Drug Administration Schedule. Drug Therapy, Combination. Enoximone / administration & dosage. Enoximone / therapeutic use. Epidemiologic Methods. Epinephrine / administration & dosage. Epinephrine / therapeutic use. Female. Humans. Male. Middle Aged. Natriuretic Peptide, Brain / blood. Nerve Tissue Proteins / blood. Norepinephrine / administration & dosage. Norepinephrine / therapeutic use. Peptide Fragments / blood. Prognosis. Shock, Cardiogenic / blood. Shock, Cardiogenic / drug therapy

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15848333.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / E-Selectin; 0 / Natriuretic Peptides; 0 / Nerve Tissue Proteins; 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain; 3S12J47372 / Dobutamine; 9007-41-4 / C-Reactive Protein; C7Z4ITI7L7 / Enoximone; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  •  go-up   go-down


47. Striuk RI, Brytkova IaV, Bukhonkina IuM, Pavlova LN: [Clinical efficacy of antihypertensive therapy of pregnant women with arterial hypertension with long acting nifedipine and bisoprolol]. Kardiologiia; 2008;48(4):29-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical efficacy of antihypertensive therapy of pregnant women with arterial hypertension with long acting nifedipine and bisoprolol].
  • Study aim was assessment of clinical efficacy of mono therapy with nifedipine SR/GITS and combination of nifedipine SR/GITS and bisoprolol as well as investigation of functional state of sympathoadrenal system (SAS) in pregnant women with arterial hypertension.
  • Examination and treatment with nifedipine SR/GITS 30 mg/day and bisoprolol 2,5 - 5 mg/day was carried out in 21 patients with stage II hypertensive disease (HD) during trimester II of pregnancy.
  • In patients with stage II HD this parameter significantly exceeded that of control group.
  • Administration of antihypertensive drugs for 3 weeks promoted significant lowering of all parameters of 24 hour blood pressure monitoring down to optimal level, lessening of pathological types of 24 hour blood pressure profile and lowering of functional activity of SAS.
  • [MeSH-major] Adrenergic beta-Antagonists / therapeutic use. Bisoprolol / therapeutic use. Blood Pressure / drug effects. Calcium Channel Blockers / therapeutic use. Hypertension / drug therapy. Nifedipine / therapeutic use. Pregnancy Complications, Cardiovascular
  • [MeSH-minor] Adult. Delayed-Action Preparations. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Pregnancy. Receptors, Adrenergic, beta / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. Nifedipine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447837.001).
  • [ISSN] 0022-9040
  • [Journal-full-title] Kardiologiia
  • [ISO-abbreviation] Kardiologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Calcium Channel Blockers; 0 / Delayed-Action Preparations; 0 / Receptors, Adrenergic, beta; I9ZF7L6G2L / Nifedipine; Y41JS2NL6U / Bisoprolol
  •  go-up   go-down


48. Smakotina SA, Trubnikova OA, Anan'ko IuA, Barbarash OL: [Effect of perindopril on cognitive functions in young and middle aged patients with hypertensive disease]. Kardiologiia; 2008;48(9):28-33
MedlinePlus Health Information. consumer health - High Blood Pressure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of perindopril on cognitive functions in young and middle aged patients with hypertensive disease].
  • We studied 40 men aged 26 - 59 years (mean age 49.0 +/- 1.9 years) with hypertensive disease (HD) and found that therapy based on the use of angiotensin converting enzyme inhibitor perindopril in young and middle aged patients with stage I and II HD appeared to be not only one of effective methods of correction of elevated arterial pressure (AP) but also of associated with it cognitive abnormalities.
  • Effect of therapy was determined by achievement of target AP values and was more pronounced in patients older than 44 years.
  • Favorable effects of perindopril in relation to parameters of cognitive functions in patients with HD allows to rate perindopril not only as effective and safe hypotensive preparation but as remedy exerting cerebroprotective effect.
  • [MeSH-major] Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Cognition / drug effects. Hypertension / drug therapy. Perindopril / therapeutic use
  • [MeSH-minor] Adult. Blood Pressure / drug effects. Blood Pressure Monitoring, Ambulatory. Female. Follow-Up Studies. Humans. Male. Middle Aged. Psychometrics / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991817.001).
  • [ISSN] 0022-9040
  • [Journal-full-title] Kardiologiia
  • [ISO-abbreviation] Kardiologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; Y5GMK36KGY / Perindopril
  •  go-up   go-down


49. Gocheva L, Koleva I: Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience. Klin Onkol; 2010;23(1):34-42
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of treatment for Hodgkin's disease: the University Hospital Sofia experience.
  • BACKGROUND: To establish the efficacy of the combined modality treatment (CMT) including curative extended field radiotherapy (EFRT) and chemotherapy (CHT) by examining the long-term outcome in Hodgkin's disease (HD) patients at the Sofia University Hospital "Queen Giovanna-ISUL", with particular focus on second primary malignancy (SPM), and to establish independent factors correlated with treatment outcome.
  • METHODS AND MATERIALS: Between 1982 and 2007, 170 patients with HD with median age of 12 years (range 3-40), (68 females, 102 males), were included in this retrospective study.
  • The clinical stage (CS) distribution was CS I in 1 patient (0.6%), CS II in 86 (50.5%), CS III in 77 (45.3%) and CS IV in 6 (3.5%) patients.
  • The overall treatment consisted of both EFRT and CHT.
  • The daily dose was 1.5-2 Gy, the total dose for EFRT was 20-40 Gy.
  • RESULTS: Follow-up extended from a minimum of 0,3 years to maximum 25,7 years, with a median observation time 12 years.The 5-, 10-, 15-, and 25-year overall survival (OS) in the whole group was 93% : 86% : 82% : 82%, respectively.
  • The following factors were analyzed for their prognostic influence: age, gender, stage, histologic subtype at first diagnosis, sites of involvement, number of involved lymph node areas, B symptoms, hepatosplenomegaly, anemia, elevated serum LDH, daily dose, total dose, boost and technique used in EFRT.
  • In univariate analysis, independent risk factors were gender (p < 0.001), stage (IIB: IIIA) (p = 0.03), mediastinal involvement (p = 0.03), daily dose (p = 0.01) and total dose (p = 0.02).
  • In multivariate analysis, independent risk factors age < or = 15 years (p < 0.001), male gender (p = 0.005), daily dose < or = 1.5 Gy (p = 0.009), and total dose 26-30 Gy (p = 0.048) were found to positively affect OS.
  • We investigated a prognostic model, identifying groups of HD patients with particularly responsive disease, combining prognostic factors as age < or = 15 years (p = 0.001), male gender (p = 0.011), and total dose 26-30 Gy (p = 0.012).
  • CONCLUSION: The performed first Bulgarian study on CMT including EFRT and CHT exhibited a certain therapeutic potential in the treatment of HD patients, expressed in the achievement of high long term outcome and low SPM frequency.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Prognosis. Risk Factors. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20192072.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


50. Cutuli B, Borel C, Dhermain F, Magrini SM, Wasserman TH, Bogart JA, Provencio M, de Lafontan B, de la Rochefordiere A, Cellai E, Graic Y, Kerbrat P, Alzieu C, Teissier E, Dilhuydy JM, Mignotte H, Velten M: Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol; 2001 Jun;59(3):247-55
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases.
  • PURPOSE: To assess the clinical and histological characteristics of breast cancer (BC) occurring after Hodgkin's disease (HD) and give possible therapies and prevention methods.
  • MATERIALS AND METHODS: In a retrospective multicentric analysis, 117 women and two men treated for HD subsequently developed 133 BCs.
  • The median age at diagnosis of HD was 24 years.
  • The HD stages were stage I in 25 cases (21%), stage II in 70 cases (59%), stage III in 13 cases (11%), stage IV in six cases (5%) and not specified in five cases (4%).
  • Radiotherapy (RT) was used alone in 74 patients (63%) and combined modalities with chemotherapy (CT) was used in 43 patients (37%).
  • Sixteen patients (12%) developed isolated local recurrence.
  • Thirty-nine patients (31.7%) developed metastases and 34 died; 38 are in complete remission whereas five died of intercurrent disease.
  • The 5-year disease-specific survival rate was 65.1%.
  • The 5-year disease-specific survival rates for the pN0, pN1-3 and pN>3 groups were 91, 66 and 15%, respectively (P<0.0001), and 100, 88, and 64% for the TIS, T1 and T2.
  • These secondary BC are of two types: a large number of aggressive tumours with a very unfavourable prognosis (especially in the case of pN>3 and/or T3T4), and many tumours with a 'slow spreading' such as DCIS and microinvasive lesions.
  • These lesions developed especially in patients treated exclusively by RT.
  • CONCLUSIONS: The young women and girls treated for HD should be carefully monitored in the long-term by clinical examination, mammography and ultrasonography.
  • Subsequent mammographies should be performed every 2 years or each year, depending on the characteristics of the breast tissue (e.g. density) and especially in the case of an association with other BC risk factors.
  • This screening seems of importance due to excellent prognosis in our T(1S)T(1) groups, and the possibility of offering these young women a conservative treatment.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / etiology. Breast Neoplasms, Male / etiology. Hodgkin Disease / complications. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Confidence Intervals. Female. Follow-Up Studies. Humans. Italy / epidemiology. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Prognosis. Retrospective Studies. Risk Factors. Spain / epidemiology. Survival Analysis. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11369065.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


51. Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T: 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial; 2010 Jun;14(3):240-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
  • The Japanese Society for Dialysis Therapy (JSDT) guideline committee, chaired by Dr Y.
  • Tsubakihara, presents the Japanese guidelines entitled "Guidelines for Renal Anemia in Chronic Kidney Disease."
  • These guidelines replace the "2004 JSDT Guidelines for Renal Anemia in Chronic Hemodialysis Patients," and contain new, additional guidelines for peritoneal dialysis (PD), non-dialysis (ND), and pediatric chronic kidney disease (CKD) patients.
  • However, the guidelines explicitly state that the target Hb level in erythropoiesis stimulating agent (ESA) therapy is different to the anemia reference level.
  • In other words, renal anemia is clearly identified as an "endocrine disease."
  • We have also emphasized that renal anemia may be treated not only with ESA therapy but also with appropriate iron supplementation and the improvement of anemia associated with chronic disease, which is associated with inflammation, and inadequate dialysis, another major cause of renal anemia.
  • In Chapter 2, which discusses the target Hb levels in ESA therapy, the guidelines establish different target levels for hemodialysis (HD) patients than for PD and ND patients, for two reasons: (i) In Japanese HD patients, Hb levels following hemodialysis rise considerably above their previous levels because of ultrafiltration-induced hemoconcentration; and (ii) as noted in the 2004 guidelines, although 10 to 11 g/dL was optimal for long-term prognosis if the Hb level prior to the hemodialysis session in an HD patient had been established at the target level, it has been reported that, based on data accumulated on Japanese PD and ND patients, in patients without serious cardiovascular disease, higher levels have a cardiac or renal function protective effect, without any safety issues.
  • However, with the results of, for example, the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) study in mind, the guidelines establish an upper limit of 12 g/dL for patients with serious cardiovascular disease or patients for whom the attending physician determines high Hb levels would not be appropriate.
  • However, if the maximum dose of darbepoetin alfa that can currently be used in HD and PD patients were to be used, then the majority of poor responders would be rescued.
  • Blood transfusions are attributed to the difficulty of managing renal anemia not only in HD patients, but also in end-stage ND patients who respond poorly to ESAs.
  • Chapter 7 discusses adverse reactions to ESA therapy.
  • Of particular concern is the emergence and exacerbation of hypertension associated with rapid hematopoiesis due to ESA therapy.
  • The treatment of renal anemia in pediatric CKD patients is discussed in Chapter 8; it is fundamentally the same as that in adults.
  • [MeSH-major] Anemia / drug therapy. Kidney Failure, Chronic / complications. Practice Guidelines as Topic. Renal Dialysis
  • [MeSH-minor] Adult. Child. Erythropoietin / administration & dosage. Erythropoietin / biosynthesis. Erythropoietin / therapeutic use. Female. Hematinics / administration & dosage. Hematinics / therapeutic use. Hemoglobins / metabolism. Humans. Japan. Male

  • Genetic Alliance. consumer health - Kidney Disease.
  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20609178.001).
  • [ISSN] 1744-9987
  • [Journal-full-title] Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • [ISO-abbreviation] Ther Apher Dial
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Hematinics; 0 / Hemoglobins; 11096-26-7 / Erythropoietin
  •  go-up   go-down


52. Yang JJ, Park SK, Cho LY, Han W, Park B, Kim H, Lee KS, Hahn SK, Cho SI, Ahn SH, Noh DY, Korean Breast Cancer Society: Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database. Clin Ther; 2010 Jun;32(6):1122-38
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.
  • OBJECTIVE: This study aimed to evaluate the cost-effectiveness of postoperative adjuvant tamoxifen therapy using data from a Korean breast cancer registry.
  • Women with stage I, II, or III breast cancer (diagnosed between 1981 and 2005), for whom information about tamoxifen use (20 mg/d for 5 years) and estrogen-receptor and/or progesterone-receptor status was available, were included.
  • Using a decision analytic model based on standard clinical flow, incremental cost-effectiveness ratios (ICERs) for overall survival were calculated with stratification by disease stage and hormone-receptor status.
  • Among those with stage I or II breast cancer, ICERs for estrogen-receptor positive (ER+)/progesterone-receptor positive (PR+) tamoxifen users ranged from $739 to $1939.
  • In contrast to those with stage I or II disease, tamoxifen use among patients with stage III disease was cost-effective regardless of hormone-receptor status.
  • CONCLUSIONS: In this analysis, postoperative adjuvant tamoxifen use was cost-effective for stage I or II ER+ and/or PR+ breast cancer, but not for ER-/PR- disease.
  • Tamoxifen therapy appeared to be cost-effective for patients with stage III breast cancer regardless of hormone-receptor status.
  • [MeSH-major] Antineoplastic Agents, Hormonal / economics. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Tamoxifen / economics. Tamoxifen / therapeutic use
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cohort Studies. Cost-Benefit Analysis. Female. Humans. Korea. Middle Aged. Neoplasm Recurrence, Local. Registries. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20637966.001).
  • [ISSN] 1879-114X
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Investigator] Ahn SH; Bae JW; Bae YT; Baek JW; Bong JG; Cha KH; Chang ES; Chang IT; Chang SS; Cho JW; Cho SH; Cho YU; Choi JW; Choi KJ; Choi MS; Choi SI; Choi SY; Goo GS; Han SH; Han W; Hong SJ; Hwang JY; Hyun TI; Im MG; Jegal YJ; Joh YG; Jun SY; Jung BW; Jung J; Jung JH; Jung KH; Jung PJ; Jung SH; Jung SS; Jung YH; Jung YS; Kang DH; Kang HJ; Kang YI; Kang YJ; Keum JH; Kim DY; Kim HJ; Kim JG; Kim JH; Kim JS; Kim JS; Kim KC; Kim SC; Kim SH; Kim SI; Kim SJ; Kim SW; Kim SW; Kim SY; Kim SY; Kim YS; Ko BK; Ko SS; Koh SH; Koo BH; Koo JY; Kwak BS; Lee CH; Lee CH; Lee DH; Lee DS; Lee ES; Lee GS; Lee HD; Lee HS; Lee JC; Lee JH; Lee JK; Lee JS; Lee JY; Lee KM; Lee KP; Lee KS; Lee KY; Lee MH; Lee RA; Lee SC; Lee SJ; Lee SK; Lee W; Lee YH; Leu JW; Lim CH; Lim CW; Moon BI; Nam SJ; Nam YS; Noh DY; Noh WC; Oh SJ; Oh SS; Pae WK; Paik IW; Paik NS; Park BG; Park BW; Park CH; Park HB; Park HY; Park JH; Park KH; Park SJ; Park ST; Park SW; Park WC; Park YK; Park YK; Seo HS; Seo KH; Seo YJ; Sin YS; Son BH; Son GS; Song BJ; Song KH; Song YJ; Suh YJ; Won JM; Woo DH; Yang DH; Yang JH; Yoo KY; Yoo SY; Yoon HS; Yoon JH; Yoon SO
  •  go-up   go-down


53. Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN: Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol; 2003 Feb;14(2):268-72
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up.
  • BACKGROUND: The most commonly used regimen for the treatment of advanced Hodgkin's disease (HD) is ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine).
  • Two of these components, bleomycin and dacarbazine, have defined toxicities such as pulmonary fibrosis and nausea/vomiting, and also uncertain single-drug activity.
  • PATIENTS AND METHODS: A series of 51 patients with advanced HD without prior systemic therapy were treated.
  • The series included 12 stage II patients with bulky (>10 cm) mediastinal tumors, 10 of whom received complementary radiation therapy.
  • Response, duration of response, survival, toxicity and the efficacy of salvage therapy were evaluated in all patients.
  • The median follow-up time was 111 months and permitted an assessment of the long-term effects of treatment and natural history of a cohort of treated patients.
  • In follow-up, 32/51 patients had no evidence of relapsed HD, although three died from other causes (two from vascular events and one from large cell lymphoma), resulting in progression-free survival for the entire group of 57% at 111 months.
  • Eight of the 16 were alive and free from disease at follow-up at 111 months.
  • In the entire series, only seven patients (14%) died of HD.
  • 37 patients (73%) continued free from disease.
  • The high salvage rate of second-line therapy, in most instances at conventional dosage, suggests an absence of cross-resistance to alkylating agents in patients treated with EVA.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12562654.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin
  •  go-up   go-down






Advertisement